Pharma BD Deal Intelligence
Insmed sold its follow-on biologics (FOB) platform — including the Phase 3 rG-CSF candidate INS-19, the Phase 1 pegylated rG-CSF INS-20, and a Boulder, Colorado biologics manufacturing facility — to Merck for $130 million in gross proceeds, with no further milestone or royalty obligations. The transaction advanced Merck's newly formed BioVentures biosimilars unit while giving Insmed non-dilutive cash to focus on its Iplex program. Announced February 2009.